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Methylene Tetrahydrofolate Reductase Gene and 
Coronary Artery Disease 
M. P. Iqbal,P. M. Frossard  ( Department of Biological and Biomedical Sciences, The Aga Khan 
University, Karachi. ) 
Hyperhomocysteinemia has been identified as a risk factor for coronary artery disease 
(CAD).1-9 In a nested case control study in Norway on 21,826 subjects in general 
population, hyperhomocysteinemia was clearly identified as an independent risk factor 
for CAD with no threshold level.9 Methylenetetrahydrofolate reductase (MTHFR) is a 
key enzyme in the methylation of homocysteine and its role in this pathway is outlined in 
Figure. Several inherited enzyme defects that can lead to elevated level of plasma 
homocysteine have been reported. Defective cystathionine b-synthase was the first to be 
extensively studied.10 However, defective remethylation of homocysteine due to 
defective MTHFR was another cause of hyperhomocysteinemia leading to premature 
vascular disease.11 
So far 10 mutations have been identified in the gene for MTHFR12,13 that result into 
decreased activity of this enzyme, which varies to a great extent. However, a 
homozygous mutation of the MTHFR gene (677C 1; ala val) alters the highly conserved 
amino acid alanine to valine, which results in compromised activity of MTHFR and leads 
to reduced methylation of homocysteine, and hence, to hyperhomocysteinemia.14 This 
variant of MTHFR had increased thermolability and was reported to be associated with 
the development of CAD.15 Since then the polymorphism of the gene of this enzyme has 
been a subject of great interest and a number of investigators have reported different 
results from a number of different populations. 
The objective of this review is to highlight the results of some of these studies and to 
emphasize the need to focus on the genetic architecture of CAD in a country, such as, 
Pakistan where this disease is quite common in the younger population.16 As a general 
rule, the earlier the onset of a complex disease (which results from interactions between 
genetic and environmental factors), the greater the role of the genetic make-up. 
Studies on MTHFR Polymorphism in Coronary Artery Disease 
During the past 10 years, there have been a number of studies in all the continents on 
investigating the effect of MTHFR gene polymorphism on the development of CAD. 
 Table summarizes the results of these studies in terms of prevalence of MTHFR gene 
variants in CAD patients and normal healthy controls in different populations. 
In addition to these studies, polymorphism of MTHFR gene has also been recently 
reported in a Chinese population17 and in a Russian population in Western Siberia.18 Both 
of these studies indicated little or no correlation of MTHFR T677 allele with coronary 
heart disease. In a recent study by Nakata et al19 , it has been postulated that the Val allele 
of MTHFR increases the relative risk for thrombosis homocysteine levels, although a 
blood pressure attenuates the disease. 
In a pervious study by Kang et a!., the prevalence of thermolabile MTHFR among CAD 
patients (n=212) compared to controls (n 202) was found to be statistically significant 
(17% vs 5% and p15. 
Effect of MTHFR Mutation on Homocysteine 
In view of the above mentioned studies, it becomes quite evident that the frequency of 
homozygotes (TT) genotype varies among different populations. The overall effect of this 
mutation on homocysteine concentration in plasma depends on study design, inclusion 
criteria, ethnic background, age and vitamin intake of the population.20 With the 
exception of a few studies21,22 most studies indicate an association of homozygous 
genotype (TI) with hyperhomocysteinemia. 
Since folate status is considered to be an important modulator of homocysteine level in 
homozygous individuals23-26, it is possible that the different homocysteine levels in 
homozygotes (IT) reported in different studies may have been due to different intakes of I 
folate by the study populations . Therefore, determination of folate level could be an 
important factor for studying the effect of genotype on homocysteine levels. Taken 
together, the facts that hyperhomocysteinemia is an established risk factor for the 
development of CAD and that reduced MTHFR activity is most commonly observed 
among IT homozygotes suggests that an association exits between the frequency of this 
genotype and risk of CAD. 
MTHFR Mutation and Risk of CAD 
A closer look at some of the studies would reveal that a stringent criteria for the selection 
of controls might be having a bearing on the outcome of that study. For example, Kang et 
al15, who have reported a clear association between homozygotes for the variant enzyme 
and the development of CAD, recruited healthy controls with no history and clinical 
evidence of arterial occlusive disease. On the other hand, in a study by Kluijtmans et al., 
that shows only a modest association, control subjects recruited from the general 
population possibly included some patients with a positive history of CAD.20 This might 
have diluted the effect of homozygous TI genotypes on the development of CAD. 
Although a number of studies have failed to show any association of homozygous TI 
genotypes with the risk of CAD, a meta-analysis on 8 different case-controlled studies on 
the thermolabile MTHFR variant in CAD indicated that the IT genotype is a modest risk 
factor for CAD.20 
MTHFR Mutation and Age 
The low frequency of a genetic risk factor in a population can contribute to the 
population’s longevity. If the MTHFR C677T mutation is a risk factor for CAD, then its 
prevalence should be less in the older population. In a study by Matsushita et al., the 
frequency of homozygous MTHFR mutation in younger Japanese population (<54 years) 
was found to be 19% compared to 7% in the older group (<90 years.27 The difference was 
statistically significant especially among males (P= 0.006) indicating that this mutation 
varies with age in the normal population, and that younger people are at a greater risk of 
developing CAD in such a population. 
This trend was also observed by Faure-Delanf et al., who reported a decreased frequency 
of MTHFR mutated allele among French centenarians (age >100 yr; 13.3%) and 
nonagenarians (age >90 years; 11.4%) compared to controls (age 20 - 70 yr; 18.5%).28 
Keeping this in view, it would be logical to assume that in studies involving older 
populations, the frequency of the variant gene would be low both in cases and controls 
and, therefore, any weak association of the variant allele with CAD would be masked. It 
is noteworthy that most studies showing an association between the MTHFR C677T 
mutation and CAD were on relatively younger populations. For example, an investigation 
on Turkish patients less than 45 years old reported a significant difference in the 
frequency of the variant MTHFR amongst cases and controls.29 Another study reported a 
similar association on Polish patients who were less than 50 years of age.30 This notion 
requires further confirmation by carrying out studies on younger populations of patients. 
MTHFR Mutation, Folate Status and Risk of CAD 
Frosst et al have identified a region in the human dihydrofolate reductase gene that bears 
a homology with MTHFR.14 This region of MTHFR might also be involved in folate 
binding, and the enzyme may be stabilized in the presence of folate. Therefore, with 
better folate status, even variant MTHFR T677 may not be associated with 
hyperhomocysteinemia, suggesting that homozygous IT genotypes may not necessarily 
be associated with increased risk of CAD in individuals with high folate levels. This 
possibility has also been highlighted by van Bockxmeer et al. in their study on Western 
Australian population31, as well as by Ma et al. in their study on well-nourished US 
physicians.26 
In a third world country like Pakistan, where folate deficiency is quite common and 
where CAD is quite prevalent in younger population16, it would be important to 
determine the role of the MTHFR gene in the development of CAD. 
Such a study will not only be of significance in unraveling the genetic architecture of 
CAD in our population but may also provide an understanding of the role of folate 
deficiency (if any) in the development of CAD. 
References  
1.Kang  SS, Wong PWK, Cook HY,et   a!.Protein-bound homocyst(e)ine: a possible risk 
factor for coronary artery disease. J Clin Invest 1986;77:1482-6. 
2.Genest JJ, McNamara JR. Salem DN, et al. Plasma hornocyst(e)ine levels in men with 
premature coronary artery disease. J Am Coil Cardiol 1990;161114-9. 
3.Williams RR. Malinow MR, Hunt SC, et al. Hyperhomocyst(e)inemia in Utah siblings 
with early coronary disease. Coron Artery Dis 1990:1:681-5. 
4.Clarke R, Daly L, Robinson K, et al. Hyperhomocysteinemia: an independent risk 
factor for vascular disease. N Eng. J Med 1991; 324:1149-55. 
5.Ubbink JB, Vermaak WJH, Bennett JM, et al. The prevalence of homocysteinemia and 
hypercholesterolemia in angiographically defined coronary heart disease. Klin 
Wochenschr 1991;69:527-34. 
6.Stampfer MJ, Malinow MR. WiIett WC, et al. A prospective study of plasma 
homocyst(e)ine and risk of myocardial infarction in US physicians. JAMA 
1992;268:877-81. 
7.Murphy-Chutorian D, Alderman EL. The case that hyperhomocysteinemia is a risk 
factor for coronary artery disease. Am J Cardiol 1994;73:705-7. 
8.Wu LL, Wu J, Hunt SC, et al. Plasma homocyst(e)ine as a risk factor for early familial 
coronary artery disease. Clin Chem 1 994;40:550-61. 
9.Amesen E, Refsum H, Bonaa K, et al. Serum total homocysteine and coronary heart 
disease. Int J. Epidemiol 1995; 24:704-9. 
10.Mudd SH, Levy HL, Skovby F. Disorders of transsulfuration. In: Scriver CR, Beaudet 
AL, Sly WS, Valle D, eds. The metabolic basis of inherited diseases. New York: 
McGraw-Hill 1989, pp. 693-734. 
11.Rosenblatt DS. Inherited disorders of folate transport and metabolism. In: Scriver CR, 
Beaudet AL, Sly WS, Valle D. eds. The metabolic Basis of Inherited Diseases. New 
York: McGraw-Hill 1989, pp. 2049-64. 
12.Goyette P. Frosst P, Rosenblatt DS, et al. Seven novel mutations in the 
methylenetetrahydrofolate reductase gene and genotype/phenotype correlations in servere 
methylenetetrahydrofolate reductase deficiency. Am J Hum Genet 1995;56:1052-59. 
13.Christensen B, Frosst P. Lussier-Cacan S, et al. Correlation of a common mutation in 
the methylenetetrahydrofolate reductase gene with plasma homocysteine in patients with 
premature coronary artery disease. Arterioscler Thromb Vase Biol 1997;17):569-73. 
14.Frosst P. Blom HJ, Milos R, et al. A candidate genetic risk fractor for vascular 
disease: a common mutation in methylenetetrahydrofolate reductase. Nat Genet 
1995;10:111-3. 
15.Kang SS, Wong PWK, Susmanbo A, et al. Thermolabile methylenetetrahydrofolate 
reductase: an inherited risk fator for coronary artery disease. Am J Hum Genet 
199l;48:536-45. 
16.Virk ZU, Khan AA, Bukhari MA. Ischemic heart disease in young population (35 
years): a clinical profile. Pak J Cardiol 1 995;6:64-6. 
17.Wang X, Gu D,. Zhao J et at. Study on relationship between 
methylenetetrahydrofolate reductase gene C677T mutation and coronary heart disease. 
Zhonghua Yi Xue Yi Chuan Xue Za Zhi 2001;18:206-8. 
18.Spiridonova MG, Stepanov VA, Pyzyrev VP et at. Relationship between 
polymorphism C677T of the methylene tetrahydrofolate reductase gene with clinical 
symptoms of coronary atherosclerosis. Genetika 2000;36:1269-73. 
19.Nakata V. Katsuya T, Takami S. et al. Methylenetetrahydrofolate reductse gene 
polymorphism: Relation to blood pressure and cerebrovascular disease. Am J Hematol 
1998;11:1019-23. 
20.Kluijtmans LAJ, Kastelein JP, Lindemans J, et al. Thermolabile 
methylenetetrahydrofolate reductase in coronary artery disease. Circulation 1 
997;96:2573-7. 
21.Schmitz C, Lindpaintner K, Verhoef P. et at. Genetic polymorphism of 
methylenetetrahydrofolate reductase and myocardial infarctions: a case-control study. 
Circulation 1 996;94: 1812-4. 
22.Wilcken DE, Wang XL, Sim AS, et at. Distribution in healthy and coronary 
population of the methylenetetrahydrofolate reductase (MTHFR) C677T mutation. 
Arterioscler Thromb Vasc Biol 1996;16:878-82. 
23.van der Put NM, Steegers-Theunissen RP, Frosst P. et at. Mutated 
methylenetetrahydrofolate reductase as a risk factor for spina bifida. Lancet 
1995;346:1070-1. 
24.Kluijtmans LAJ, van den Heuvel LP, Boers GHJ, et a!. Molecular genetic analysis in 
mild hyperhomocysteinemia: common mutation in the methylenetetrahydrofolate 
reductase gene is a genetic risk factor for cardiovascular disease. Am J HumGenet 
1996,58:35-41. 
25.Jacques PF, Boston AG, Williams RR, et at. Relation between folate status, a common 
mutation in methylenetetrahydrofolate reductase and plasma homocysteine concentration. 
Circulation I 996;93:7-9. 
26.Ma J, Stampfer MJ, Hennekens CH, et al Methylenetetrahydrofolate reductase 
polymorphism, plasma folate, homocysteine, and risk of myocardial infarction in US 
physicians. Circulation 1996; 94:2410-16. 
27.Matsushita S,Muramatsu T, Arai H, et at. The frequency of the 
methylenetetrahydrofolate reductase-Gene mutation varies with age in the normal 
population. Am J Hum Genet 1997;61:1459-60. 
28.Faure-Delanef L, Quéré 1, Chasse J.F, et at. Methylenetetrahydrofolate reductase 
thermolabile variant and human longevity. Am J Hum Genet 1997;60:999-1 001. 
29.Gulec S. Aras 0, Akar E, et at. Methylenetetrahydrofolate reductase gene 
polymorphism and risk of premature myocardial infarction. Clin Cardiol 2001 ;24:281-4 
30.Szczeklik A, Sanak M, Jankowski M, et al. Mutation A1298C of 
methylenetetrahydrofolate reductase: risk for early coronary disease not associated with 
hyperchomocysteinemia. Am J Med Genet 2001;101:36-9. 
31.van Bockxmeer FM,Mamotte CD,Vasikaran SD,et at. Methytenetetrahydrofolate    
reductase gene and coronary artery disease. Circulation 1997; 95:21-3. 
32.Adams M, Smith PD,Martin D,et al.Genetic analysis of thermolabile 
methylenetetrahydrofolate reductase as a risk factor for myocardial infarction. Q J Med 
l996:89;437-44. 
33.Gallagher PM, Meleady R, Shields DC, et at. Homocysteine and risk of premature 
coronary heart disease. Evidence for a common gene mutation. Circulation 
1996;94:2154-8. 
34.Schwartz SM. Siscovick DS, Malinow MR, et al. Myocardial infarction in young 
women in relation to plasma total homocysteine, folate and a common variant in the 
methylenetetrahydrofolate reductase gene. Circulation 1997:96:412-7. 
35.Brugada R, Marian AJ. A common mutation in methylenetetrahydrofolate reductase 
gene is not a major risk of coronary artery disease or myocardial infarction. 
Atherosclerosis 1997; 128:107-12. 
36.Morita H, Taguchi J, Kurihara H, et at. Genetic polymorphism of 5, 10 
methytenetetrahydrofotate reductase (MTHFR) as a risk factor for coronary artery 
disease. Circulation 1997;95 :2032-6. 
37.Anderson JL, King GJ, Thomson MJ, et at. A mutation in the 
methytenetetrahydrofotate reductase gene is not associated with increased risk for 
coronary artery disease or myocardiat infarction. J Am Colt Cardiot 1997:30:1206-11. 
38.OuT,Yamakawa-Kobayashi K, Arinami T, et al. Methylenetetrahydrofolate reductase 
and apoliopoprotein E polymorphisms are independent risk factors for coronary heart 
disease in Japanese: a case-control study. Atherosclerosis 1998; 137:23-8. 
39.Goracy I, Goracy J, Suliga M, et at. C677T gene polymorphism of 
methylenetetrahydrofolate reductase (MTHFR) in patients with myocardiat infarction. 
Pol Arch Med Wewn 1999;102:849-54. 
40.Zheng YZ, Tong J, Do X.P,et at. Prevalence of methylenetetrahydrofolate reductase 
C677T and its association with arterial and venous thrombosis in the Chinese population. 
Br J Haematol 2000;109:870-4. 
41.Hanson NQ, Aras 0, Yang F, et at. C677T and A1298C polymorphisms of the 
methylenetetrahydrofolate reductase gene: incidence and effect of combined genotypes 
on plasma fasting and post-methionine load homocysteine in vascular disease. Clin Chem 
2001;47:661-6. 
42.Meisel C, Cascorbi I, Gertoff T, et al. Identification of six methylenetetrahydrofolate 
reductase (MTHFR) genotypes resulting from common polymorphisms: impact on 
plasma homocysteine levels and development of coronary artery disease. Atherosclerosis 
2001 ;1 54:651-8. 
43.Raslova K, Smolkova B, Vohnout B, et at. Risk factors for atherosclerosis in survivors 
of myocardial infarction and their spouses: comparison to controls without personal and 
family history of atherosclerosis. Metabolism 2001 ;5:24-9. 
